Concepedia

Tim Bruemmendorf

TB

3

Publications

78

Citations

3

H-Index

2007

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of Applied Sciences Mainz

Universität Hamburg

University of Milano-Bicocca

University of Bologna

Tim Bruemmendorf is an author at The University of Texas MD Anderson Cancer Center specializing in pharmacotherapy, gene therapies, and cellular therapies.

Top concepts

Publications per year

2007–2008

3

Publications

3

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

Carlo Gambacorti‐Passerini, Hagop M. Kantarjian, Tim Bruemmendorf et al. · Blood · 2007 · 34 citations

Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).

Jörge E. Cortes, Tim Bruemmendorf, Hagop M. Kantarjian et al. · Blood · 2007 · 24 citations

Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Tim Bruemmendorf, Francisco Cervantes, D. Kim et al. · Journal of Clinical Oncology · 2008 · 20 citations

, , +17

Rows per page

1–3 of 3